There are 2949 resources available
808MO - Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
Presenter: Florence Joly Lobbedez
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
813MO - Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
Presenter: Jean-Sebastien Frenel
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
809MO - Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint)
Presenter: David Cella
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
810MO - Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Presenter: Bhavana Pothuri
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
811MO - Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Presenter: Susana Banerjee
Session: Mini Oral - Gynaecological cancers 1
Resources:
Abstract
Slides
Webcast
1586MO - Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe
Presenter: Kerstin Vokinger
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1587MO - How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature
Presenter: Karla Hernandez Villafuerte
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1588MO_PR - A comparative study on costs of cancer and access to medicines in Europe
Presenter: Nils Wilking
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1589MO - Opposition to a patent covering tisagenlecleucel: Using intellectual property (IP) legislation to defend sustainable access to cancer therapies
Presenter: Juliana Veras
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1590MO - Income loss after a cancer diagnosis from the patient perspective: An analysis based upon the German Socio-Economic Panel (SOEP) survey
Presenter: Diego Hernandez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast